IQVIA™ Real-World Insights Bibliography

The Burden Of Hpv In Head And Neck Cancers - Design Of The Broaden Study
Author(s): Gómez Ulloa D1, Morais E2, Fenoll R1, Kothari S3, Giuliano A4, Mirghani H5, Mehanna H6, Waterboer T7, Roberts C3, Varga S3, Tu Y3, Pérez G3, Saah A3, Alemany L8
Affiliations(s): 1 IQVIA, Barcelona, Spain 2 MSD, CORE, Lyon, France 3 Merck & Co. Inc., Center for Observational and Real-world Evidence, Kenilworth, NJ, US 4 Moffitt Cancer Center and Research Institute, Center for Immunization and Infection Research in Cancer, Tampa, FL, US 5 HEGP, ORL, Paris, France 6 InHANSE, Head and Neck Surgery, Birmingham, UK 7 German Cancer Research Center (DKFZ), Infections and Cancer Epidemiology, Heidelberg, Germany 8 Catalan Institute of Oncology - IDIBELL, On behalf of Unit of Cancer and Infection in the Cancer Epidemiology Research Programme, Hospitalet Del Llobregat, Spain
Publication(s):  IPVC, Barcelona, Spain, 23-27 March 2020
Document Type(s): Oral presentation,
Countries: China, France, Germany, Italy, Japan, Portugal, Spain,
C:
Y:
Infectious disease, Oncology,
2020
  L:
A:
English
Burden of illness, Observational study, Retrospective Field Study,
  Add to report
 
 
Real-world clinical outcomes for third-line standard of care regimens in deficient mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC) in France
Author(s): Cohen R1, Thierry A1, Roset M2, Amonkar M3, Patel R3, Lara N2, Kothari S3, Tougeron D4
Affiliations(s): 1 Sorbonne Université, medical oncology department, AP-HP, hôpital Saint-Antoine, F-75012 Paris, France 2 IQVIA, Barcelona, Spain 3 Merck & Co, Inc., Kenilworth, NJ, US 4 Gastroenterology Department, Poitiers University Hospital and University of Poitiers, Poitiers, France
Publication(s):  ESMO GI, Barcelona, Spain 1-4 July 2020
Document Type(s): Poster,
Countries: France,
C:
Y:
Oncology,
2020
  L:
A:
English
Observational study, Population Based Study, Retrospective Field Study,
  Add to report
 
 
Real-world treatment patterns, healthcare resource use and clinical outcomes of patients receiving second line therapy for advanced or metastatic gastric cancer
Author(s): Gomez-Ulloa D1, Amonkar M2, Kothari S3, Cheung WY4, Chau I5, Zalcberg J6, Lara N1, Falcone A7
Affiliations(s): 1 IQVIA, Barcelona, Spain 2 Merck & Co., Inc., North Wales, PA, US 3 Merck & Co., Inc., Kenilworth, NJ, US 4 British Columbia Cancer Agency, Vancouver, BC, Canada 5 Royal Marsden Hospital, London, UK 6 Alfred Health, Melbourne, Australia 7 University of Pisa, Pisa, Italy
Publication(s):  BMC Gastroenterology
BMC Gastroenterology volume 20, Article number: 133 (2020)
Document Type(s): Article,
Countries: Australia, Canada, Italy, UK,
Click here for the abstract
C:
Y:
Oncology,
2020
  L:
A:
English
Retrospective cohort analysis,
  Add to report
 
 
Nivolumab-treated non-small cell lung cancer patients in the United Kingdom
Author(s): Carroll R1, Tanna N1, Ghosh S2, Sanchez E3, Stawiarska Z4, Gemmen E5
Affiliations(s): 1 Bristol-Myers Squibb, Uxbridge, UK 2 IQVIA, Gurugram, India 3 IQVIA, Barcelona, Spain 4 IQVIA, Warsaw, Poland 5 IQVIA, Rockville, MD, US
Publication(s):  BMC Gastroenterology
Document Type(s): Article,
Countries: UK,
C:
Y:
Oncology,
2020
  L:
A:
English
Observational study, Population Based Study, Retrospective Field Study,
  Add to report
 
 
Annualized Hospitalization Rate With Natalizumab vs Fingolimod in Second-Line Treatment for RRMS in the Public Healthcare System in Brazil: A Claim Database Approach
Author(s): Guilherme Silva Julian 1, Ricardo Papaléo Rosim 2, Estela Cristina Carneseca 3, Jéssica Rigolon 2
Affiliations(s): 1 IQVIA Brasil, São Paulo-SP, Brazil. 2 Biogen Brasil, São Paulo-SP, Brazil. 3 Proestat Consultoria Estatística, Ribeirão Preto-SP, Brazil.
Publication(s):  PMID: 32119696 PMCID: PMC7051079 DOI: 10.1371/journal.pone.0229768
Document Type(s): Article,
Countries: Brazil,
Click here for the abstract
C:
Y:
Oncology,
2020
  L:
A:
English
Retrospective database analysis,
  Add to report
 
 
Descriptive study on perceptions and communication of fatigue among castration resistant prostate cancer (CRPC) patients in Japan
Author(s): Iguch.T1, Nakamura.Y2, Akiyama.T3, Krishant C3, Yu E3
Affiliations(s):  1 Osaka City University Graduate School of Medicine Urology and Pathology, 2 Bayer Yakuhin Co., Ltd. Market Access Headquarters, 3 IQVIA Solutions Japan Co., Ltd. Real World Evidence Solutions
Publication(s):  Accepted Presentation Japanese Urological Association 2020
Document Type(s): Abstract,
Countries: Japan,
C:
Y:
Oncology,
2020
  L:
A:
English
Survey research,
  Add to report
 
 
Patient preferences, treatment satisfaction, and quality of life in newly diagnosed and relapsed/refractory multiple myeloma patients receiving injectable-containing or fully oral therapies: the EASEMENT study
Author(s): Neil Rabin1, Rami Kotb2, Athanasios Zomas3, Alonso Fernandez-Nistal3, Rocco D?Ambrosio3, Nawal Bent-Ennakhil3, Montserrat Roset4, Ombretta Annibali5
Affiliations(s): 1 University College London Hospitals, London, and North Middlesex University Hospital, UK; 2 CancerCare Manitoba, Winnipeg, Manitoba, Canada; 3 Takeda Pharmaceuticals International AG, Zurich, Switzerland; 4 IQVIA, Barcelona, Spain; 5 Università Campus Bio-Medico di Roma, Rome, Italy
Publication(s):  COMy (the 6th World Congress on Controversies in Multiple Myeloma), Virtual congress, 3-4 October 2020
Document Type(s): Poster,
Countries: Canada, Italy, UK,
C:
Y:
Hematology, Oncology,
2020
  L:
A:
English
Population Based Study,
  Add to report
 
 
Modernizing Regulatory Evidence with Trials and Real-World Studies
Author(s): Nancy A. Dreyer PhD, MPH, FISPE, Marni Hall PhD, MPH & Jennifer B. Christian PharmD, MPH, PhD, FISPE
Affiliations(s): IQVIA Real World Solutions, 201 Broadway, 5th Floor, Cambridge, MA, 02139, USA Nancy A. Dreyer PhD, MPH, FISPE IQVIA Real-World Solutions, Rockville, MD, USA Marni Hall PhD, MPH IQVIA Real World Solutions, Research Triangle Park, NC, USA Jennifer B. Christian PharmD, MPH, PhD, FISPE
Publication(s):  Ther Innov Regul Sci (2020). https://doi.org/10.1007/s43441-020-00131-5
Document Type(s): Article,
Countries: USA,
Click here for the abstract
C:
Y:
Oncology,
2020
  L:
A:
English
Retrospective database analysis,
  Add to report
 
 
Real-world treatment patterns and clinical outcomes in patients receiving second-line (2L) treatment for advanced or metastatic gastric cancer (GC)
Author(s): Amonkar M1, Gomez-Ulloa D2, Smita Kothari1, Cheung WY3, Chau I4, Zalcberg JR5, Lara N2, Falcone A6
Affiliations(s): 1 Merck & Co., Inc., Kenilworth, NJ, USA 2 IQVIA, Barcelona, Spain 3 British Columbia Cancer Agency, Vancouver, BC, Canada 4 Royal Marsden Hospital, London, UK 5 Alfred Health, Melbourne, Australia 6 University of Pisa, Pisa, Italy
Publication(s):  BMC Gastroenterology volume 20, Article number: 133 (2020)
Document Type(s): Poster,
Countries: Australia, Canada, Italy, UK,
C:
Y:
Oncology,
2019
  L:
A:
English
Retrospective cohort analysis,
  Add to report
 
 
Cost-offsets in relapsed/refractory multiple myeloma and resource consumption derived from Italian real practice
Author(s): Ripellino C, Pegoraro V, Heiman F
Affiliations(s): Ripellino C: HEOR Consultant Freelance, Milan, Italy. Pegoraro V: Medical Writer & HEOR Consultat, IQVIA, RWS, Milan, Italy. Heiman F: HEOR Engagement Manager, IQVIA, RWS, Milan, Italy
Publication(s):  CLINICO ECONOMICS ITALIAN ARTICLES ON OUTCOMES RESEARCH / VOL 14 / YEAR 2019 / PAG. 55-64
Document Type(s): Article,
Countries: Italy,
Click here for the abstract
C:
Y:
Health economics, Oncology,
2019
  L:
A:
Italian
Cost analysis,
  Add to report
 
 
 1 of 58 Next Page Last Page